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Abstract: A small library of truncated neomycin-conjugates is prepared by consecutive 
removal of 2,6-diaminoglucose rings, oxidation-reductive amination of ribose, oxidation-
conjugation of aminopyridine/aminoquinoline and finally dimerization. The dimeric 
conjugates were evaluated for antibacterial activity with a unique hemocyanin-based 
biosensor. Based on the outcome of these results, a second-generation set of monomeric 
conjugates was prepared and found to display significant antibacterial activity, in particular 
with respect to kanamycin-resistant E. coli. 
Keywords: aminoglycosides; morpholine; aminopyridine; aminoquinoline; hemocyanin; 
biosensor; fluorescence 
 
Introduction 
Aminoglycosides, a group of naturally occurring compounds obtained from actinomycetes of the 
genus Streptomyces or Micromonospora [1] are in clinical use as antibiotics as a result of their broad 
antimicrobial spectrum and rapid bactericidal effects [2]. Aminoglycosides bind to 16S ribosomal 
RNA at the tRNA acceptor A-site (aminoacyl site), and affect the ability of the ribosome to decode 
mRNA correctly during protein synthesis [3–5]. Unfortunately, toxic side effects and growing bacterial 
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resistance [6,7] have narrowed the significance of aminoglycosides as antibiotics. The most common 
mechanism of resistance is the enzymatic modification of one or more functional groups of the 
aminoglycoside drug by bacterial enzymes [8–10]. Due to these limitations, aminoglycosides are the 
focus of attention of research groups around the world and numerous structural analogues of the 
aminoglycosides have been synthesized over the years [11–13]. The main objective of the synthetic 
modifications of the aminoglycosides is to circumvent the bacterial resistance without loss in binding 
affinity of these drugs. In the majority of studies, naturally occurring aminoglycosides are modified by 
regioselective diversifications of the appropriate functional groups while keeping the whole structure 
intact [14–21]. However, it is clear that structures with a high resemblance to the natural compounds 
are most likely to undergo modification by bacterial resistance enzymes. Therefore, unlike this strategy 
we intended to utilize a minimal core element for the development of new structural analogues. 
Because bacterial enzymes have evolved to modify the structures of naturally occurring 
aminoglycosides, stripping off the targeted alcohol and amino functions evades the problem of 
bacterial resistance. On the other hand, such a strategy will concomitantly also reduce antibacterial 
activity because the same heteroatoms are responsible for RNA binding. Therefore, in order to restore 
affinity, lost by functional group removal, we envisaged conjugation of such a truncated 
aminoglycoside with a non-aminoglycoside type RNA ligand. Such a strategy has earlier proven 
successful for conjugation of native aminoglycosides to acridines [22,23], nucleobases [24], 
nucleotides [25], peptides [26,27], and other antibiotics [28]. Also, diversification of neamine as a 
structural motif for the synthesis of RNA ligands has been explored by several research groups  
[29–33]. However, neamine still contains the diaminosugar ring I of aminoglycosides, and is therefore 
a substrate for several resistance enzymes. Dimeric aminoglycoside have also divulged an improved 
RNA binding than individual aminoglycosides [34–43], therefore we made the dimers of our 
conjugates with conformationally adaptable linkers to further enhance binding affinity. These 
compounds were then tested for antibacterial activity against E. coli with a fluorescence-based assay. 
Results and Discussion 
Synthesis of 5-O-Morpholino-2-Deoxystreptamine 
Our strategy is based on the fundamental observation that the key structural feature of (nearly) all 
aminoglycosides is not a carbohydrate but a diaminocyclohexitol ring termed 2-deoxystreptamine [44]. 
It was hypothesized that 2-deoxystreptamine is a crucial scaffold to build aminoglycoside libraries and 
that the all-equatorial substitution pattern is highly favorable to position other pharmacophores in the 
proper orientation. Although a large number of synthetic routes to 2-deoxystreptamine have been 
developed over the years [44], including contributions from our own lab [45–48], we realized that the 
most straightforward and cheapest route to 2-deoxystreptamine commences from natural neomycin. 
Apart from that, we surmised that partial degradation of neomycin would leave the ribofuranoside as a 
suitable substituent at the 5-position of 2-deoxystreptamine, as in structure 2 (Scheme 1). Thus, N-Boc-
protected neomycin 1 [49] was reacted with 12 equivalents of sodium metaperiodate resulting in the 
oxidative cleavage of vicinal diols on both 2,6-diaminosugars. The intermediate tetraaldehyde was not 
purified due to its instability, but upon base treatment underwent smooth β-elimination under the 
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influence of an amine base, to give 5-O-ribosyl-2-deoxystreptamine 2. Use of different bases like n-
butyl amine, ammonium hydroxide and triethylamine gave the same results in terms of yield and 
reaction time. Importantly, 2 was purified by direct recrystallization from dichloromethane leading to 
highly pure product 2 in a 48% average yield over the two steps. The resulting pseudodisaccharide 2 
was once again subjected to sodium metaperiodate cleavage of the diol to give a dialdehyde, this time 
followed by reductive amination with propargylamine, to afford morpholine 3 substituted with an 
acetylene moiety. Unfortunately, the formation of open chain diamine side products could not be fully 
avoided, thus significantly suppressing the yield. 
Scheme 1. Synthesis of acetylene-substituted morpholino-2-deoxystreptamine conjugate. 
Reagents and conditions: a) NaIO4, H2O, MeOH, overnight (o.n.); b) Et3N, MeOH, o.n. (45–52%). c) i. NaIO4, 
MeOH, H2O, 2 h, ii. propargylamine, NaBH3CN, AcOH, MeOH, 1 h (41%). 
Synthesis and Conjugation of Aminopyridines and Aminoquinolines 
As aminoglycoside antibiotics function by selective recognition and binding to a specific RNA 
sequence, the removal of two of the aminoglycopyranosides is detrimental for RNA affinity. 
Therefore, we opted to restore the binding affinity by conjugation with other RNA ligands. To this end, 
we surmised that aminopyridines and aminoquinolines [50] could nicely serve our purpose because 
these molecules are of low molecular weight and contain no aliphatic amine functionality, but 
nevertheless have been reported to bind with E. coli A-site RNA in micromolar range. We selected the 
two tightest binders from the series of aminopyridines, e.g., 2-(2-aminoethylamino)-4-methylpyridine 
and 2-(2-aminoethylamino)-5-methylpyridine, and the best aminoquinoline ligand 2-(2-
aminoethylamino)-4-methylquinoline (Scheme 2). In order to be able to conjugate the arylamine 
ligands to our morpholine compound, we designed a route involving reductive amination via the 
primary alcohol of 3. Therefore, we first prepared derivatives of the arylamines by treating the 
commercially available chloropyridines and a chloroquinoline with 1,2-ethylenediamine at 150 °C for 
18 hours as shown in the Scheme 2, to afford the desired 2-aminoethyl modified arylamines 5–7 in 
reasonable yield.  
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Scheme 2. Synthesis of substituted aminopyridines and aminoquinolines. 
 
Reagents and conditions: a) 1,2-ethylenediamine, 150 °C, 20 h (5: 46%, 6: 51%, 7: 48%). 
Having the primary amines at hand, the next step involved the diversification of morpholine 3 by 
conjugation with the aminoethyl derivatives 5–7. For this purpose the primary hydroxyl of the 
compound 3 appeared most appropriate since it is most accessible and leaves the chiral secondary 
alcohols of 2-deoxystreptamine intact. Since reductive amination is such a robust conjugation 
technology, we aimed to selectively oxidize the primary alcohol of 3. Because it is known that Swern 
oxidations can be selectively executed at O-TES protected primary alcohols [51], we treated 
compound 3 with TESOTf and triethylamine in dichloromethane to protect all hydroxyls with the TES 
group. Subsequently, the triply TES-protected derivative was subjected to Swern oxidation conditions 
(oxalyl chloride, DMSO, -78 °C→0 °C), in order to selectively oxidize the primary hydroxyl. 
However, an inseparable mixture of compounds was obtained (Table 1, entry 1). 
Scheme 3. Conjugation of morpholine to aminopyridines and aminoquinolines. 
 
Because Swern oxidation of TES ethers was not successful, we opted for a selective oxidation of 
the primary alcohol without protective groups. However, attempts to oxidize the primary hydroxyl 
with TCCA/TEMPO [52] (entry 2) or IBX [53] (entry 3) gave no or less than 10% conversion, 
respectively. Finally, we succeeded (entry 4) in oxidizing the primary hydroxyl group with Dess-
Martin periodinane [54] to give selectively the desired aldehyde 4b. However, also in this case the 
reaction did not go to completion, reaching a maximum of about 60% conversion. Further attempts to 
optimize the reaction conditions, e.g., variation in temperature, solvents or stoichiometry of the oxidant 
did not improve the outcome.  
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Table 1. Conditions for selective oxidation of primary alcohal. 
Entry Conditions Product Yield 
1 
i) TESOTf, Et3N, CH2Cl2, r.t., 3 h 
ii) (COCl)2, DMSO, CH2Cl2, -78 
°C→0 °C 
4a 
mixture 
2 TCCA, TEMPO, CH3CN, r.t., 16 h 4b no reaction 
3 IBX, DMF, r.t.→80 °C, 16 h 4b <10% conversion 
4 DMP, DMF, r.t., 16 h 4b 60% conversion 
Reagents and conditions: a) 5/6/7, NaBH3CN, AcOH, MeOH, 3 h. b) Boc2O, DMAP, CH2Cl2, 4 h 
(9a: 34%, 9b: 37%, 9c: 32%, for two steps). 
The resulting aldehyde 4b was subjected to the next reaction without purification on account of its 
instability. We therefore proceeded to couple crude aldehyde 4b with aminopyridine and 
aminoquinoline derivatives 5–7 (Scheme 3). Therefore, compounds 5–7 were condensed with aldehyde 
4b employing standard reductive amination conditions, e.g., NaBH3CN and AcOH in methanol. The 
relatively low yields of the resulting compounds 8a-c can be ascribed to incomplete oxidation of the 
compound 3 in the proceeding step, apart from the fact that accompanying dialkylation of amines was 
observed during the reductive amination. However, in this case the desired conjugates 9a-c could be 
readily purified by silica gel column chromatography. Both for this purpose and for follow-up 
chemistry, it was found most convenient to convert the resulting secondary amino functions of the 
initial products 8a-c into Boc-protected carbamates under the influence of Boc2O and DMAP in 
CH2Cl2. Thus, heteroconjugates 9a-c of truncated neomycin with non-aminoglycoside type RNA 
ligands were successfully prepared. 
Dimerization and Deprotection of the Conjugates 
Obviously, the obtained arylamine-morpholine-2-deoxystreptamine conjugates contain a functional 
handle at the morpholine ring in the form of the propargyl moiety. Based on the popular copper(I)-
catalyzed azide acetylene cycloaddition (CuAAC) [55,56], it is clear that the propargyl moiety 
provides an excellent handle for the preparation of further conjugates. Therefore, we next utilized the 
copper-catalyzed (3+2) cycloaddition chemistry to make 683 immers with a range of mono- and 
bisazido-functionalized linkers. This approach provided maximum synthetic flexibility and proved 
effective for the synthesis of various monomers and 683immers from the building blocks 9a-c. Thus, 
the synthetic heteroconjugates were treated with a monoazide (benzyl azide, 1 equiv.) or bisazides A-E 
(0.5 equiv.) in a mixture of water and acetonitrile in the presence of copper-wire [57] to make the 
respective monomers 9a-cE and dimers 9a-cA to 9a-cD in reasonable to good yields (Table 2). 
Finally, acidic deprotection of the Boc protective groups was performed in a 1:2 mixture of TFA and 
DCM to afford the respective monomers and the dimers in quantitative yields, giving a final set of 15 
arylamine-aminoglycoside conjugates (3 monomers, 12 dimers). For biological evaluation, all of the 
compounds were purified by reversed phase HPLC, giving the pure conjugates in 5–20 mg quantitities.  
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Scheme 4. Dimerization and deprotection of the conjugates. 
 
Reagents and conditions: a) L, CH3CN, H2O, Cu wire, o.n. b) CH2Cl2, TFA, 3 h (quantitative). 
Table 2. Linkers used for synthesis of dimers 9aA-9cE. 
Entry Linker (L) Starting 
material 
Product Yield 
1 
2 
3 
 
9a 
9b 
9c 
9aA 
9bA 
9cA 
63% 
73% 
60%
4 
5 
6  
9a 
9b 
9c 
9aB 
9bB 
9cB 
57% 
65% 
58%
7 
8 
9 
9a 
9b 
9c 
9aC 
9bC 
9cC 
61% 
66% 
69%
10 
11 
12 
 
9a 
9b 
9c 
9aD 
9bD 
9cD 
60% 
65% 
66%
13 
14 
15  
9a 
9b 
9c 
9aE 
9bE 
9cE 
87% 
92% 
90%
Evaluation of Antibacterial Activity 
Having prepared the desired conjugates, we were interested to investigate the antibacterial activity 
of these compounds. Determination of antibacterial activity is normally expressed in MIC (minimal 
inhibitory concentration) by growing bacteria in medium containing increasing amounts of the 
presumed antibiotic. Such an assay typically requires substantial amounts of compounds (30–70 mg), 
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clearly exceeding the amount of compound that we had prepared. With small amounts of substrate, 
antibacterial activity can also be determined with Kirby-Bauer disc test, but that provides only a 
qualitative measure of activity. Alternatively, a plethora of RNA-binding assays have been developed 
[58–69], but a strong drawback of such assays is that they do not include cell-wall penetration or 
resistance mechanisms, obviously key in determining the overall activity of an antibiotic [70]. An 
alternative approach, recently reported by some of us [71], determines MICs on whole bacteria in a 
simple and rapid assay and moreover requires only minimal amounts (< 2 mg) of substrate. The 
technique relies on a fluorescence-based cell viability assay and involves a hemocyanin-based oxygen 
biosensor to monitor oxygen consumption of bacteria and subsequently bacterial cell growth  
(Figure 1). 
Figure 1. (A) Representation of Cy3-labeled hemocyanin. The Cy3 dye (cyan) is showed 
attached to the end terminus of a monomer hemocyanin. (B) Detail of hemocyanin active 
site showing the active site histidines (blue), copper ions (orange) and the binding oxygen 
molecule (red). (C) The absorption spectra of the deoxygenated (red) and oxygenated 
(blue) forms of hemocyanin together with the emission spectrum of Cy3 (green). 
 
Deoxygenated hemocyanin has no absorption in the visible spectrum but upon oxygenation a strong 
band centered at 340 nm and a weak band around 570 nm appear (Figure 1B). If a fluorescent label is 
attached to the N-terminus of hemocyanin, this change in absorption can be translated into a change of 
fluorescence intensity of an attached label (Cy3, Cyanine 3 fluorescent dye) through a Förster 
resonance energy transfer (FRET) mechanism (Figure 1A) [72]. The efficiency of this energy transfer 
depends on the distance and orientation between the donor and the acceptor and also on the overlap 
integral between the donor emission and acceptor absorption spectra (Figure 1C). In this way, when 
the protein is in its deoxygenated state (Cy3-Deoxy-Hemocyanin), all the energy absorbed by the label 
is emitted normally as fluorescence. Upon oxygenation of hemocyanin (Cy3-Oxy-Hemocyanin), 
energy is transferred from Cy3 by radiationless decay to the copper center of hemocyanin, resulting in 
a decrease in the fluorescence intensity. Thus, when a bacterial culture grows aerobically, oxygen in 
the medium is gradually consumed. This results in a drop of the oxygen concentration, eventually 
resulting in an anaerobic medium. When hemocyanin-based oxygen biosensor is present, this oxygen 
depletion results in an increase of the fluorescence intensity emitted by the Cy3 label attached to 
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protein [71].Error! Bookmark not defined. Tests were carried out as describedError! Bookmark 
not defined. [71] with an initial cell concentration of 105 cfu/mL. 
Figure 2. Fluorescence intensity time traces at 570 nm (excitation 550 nm) of cultures of 
E. coli containing Cy3-labeled  hemocyanin as a function of antibiotic concentration. 
Antibiotic concentrations of 9cA and 9cB are stated. 
 
We determined the MICs of our heteroconjugates with the fluorescence-based cell viability assay 
against several bacterial strains (E. coli, E. coli kan.r e.g., kanamycin-resistant E. coli) using 
kanamycin as a positive control. As can be seen from Figure 2, using compound 9cA and 9cB as an 
example, the MIC is determined by performing the bacterial growth in medium containing increasing 
amounts of our compounds. The MIC values of our synthetic analogues can be determined from Figure 
2 and are depicted in Table 3. 
Table 3. MIC values (µg/ mL) as determind by the fluorescence-based cell growth assay. 
Entry bacterial strain 
MIC (μg/ mL) 
kanamycin s.m. 
linker  
A 
linker 
B 
linker 
C 
linker 
D 
linker 
E 
1 E. coli 10 9a 200–400 200–400 400–800 400–800 400–800 
2 -do- 10 9b 400–800 400–800 400–800 400–800 400–800 
3 -do- 10 9c 200–400 100–200 200–400 400–800 200–400 
Second Generation Monomeric Ligands 
Unfortunately, our set of dimers of heteroconjugates exhibited lower antibacterial activity than that 
of natural kanamycin when tested against E. coli. In fact, only compound 9cB demonstrated reasonable 
antibacterial activity. Moreover, and in contrast to expectation, it is clear that the dimers do not show 
improved activity compared to the monomeric substrates 9a-cE. 
 
Pharmaceuticals 2010, 3              
      
 
687
Scheme 5. Synthesis and deprotection of monomeric ligands. 
   
Reagents and conditions: a) R-N3, CH3CN, H2O, Cu-wire, 16 h (70–80%). b) CH2Cl2, TFA, 3 h 
(quantitative); a azides were reduced with PMe3 prior to Boc removal. 
The lack of improved activity is in contrast to findings by other groups [34–43], which may be 
explained in our case by the relatively short linkers employed. It is not excluded that a short linker is 
precluding cooperative binding of the other end of the molecule to a second binding pocket. Whatever 
the reason, the fact that the MIC value of the monomeric compound 9cE was comparable to that of 
different dimers stimulated us to explore whether antibacterial activity of the more simple, monomeric 
heteroconjugates could be further raised by modification of the azide partner for cycloaddition to the 
acetylene. Thus, we selected a range of aromatic and aliphatic azides and coupled these to acetylene 
derivatives 9a-c with CuAAC to obtain a set of monomeric compounds 10a-g with different 
substituents (Scheme 5). Thus, compounds 10a–e were synthesized by simply treating 9c with 
different monoazides in a mixture of water and acetonitrile in the presence of copper wire. For the 
synthesis of amino-terminated compounds 10f and 10g, acetylene 9c was treated with an excess of  
1,4-bis(azidomethyl)benzene or 1,5-diazidopentane, to give the respective monosubstituted triazole 
adducts, followed by Staudinger reduction of the unreacted azide group at the other chain terminus 
under the action of PMe3. Again, all compounds 10a-g were purified to homogeneity by reversed-
phased HPLC before evaluation of antibacterial activity. Next, we tested the antibacterial activity of 
this set of compounds employing the same fluorescence-based cell viability assay and the results are 
summarized in Table 3. As evident from MIC values, para-bromo substitution of the aromatic ring 
enhanced the antibacterial activity of compounds 10a and 10b. The rest of the monomeric compounds, 
with a methoxy- or methylamino-substituent on the aromatic ring 10c-10f, or with the aliphatic chain 
10g showed a reduced antibacterial activity compared to that of unsubstituted parent compound 9cE. 
Finally we tested the MIC of the most active compounds against the kanamycin resistant strains of  
E. coli (Table 4, entry 2). We were happy to find that compounds 10a and 10b have distinct 
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antibacterial activity against E. coli. More importantly, compound 10b displayed an improved activity 
against the kanamycin-resistant E. coli strain revealing that omission of the diaminoglycosides indeed 
fulfills our desired aim to reduce susceptibility to resistance mechanisms. The search for further 
synthetic analogues of aminoglycosides with such improved traits is currently ongoing in our 
laboratory. 
Table 4. MIC values (μg/mL) as determined by fluorescence-based cell growth assay. 
Entry 
bacterial 
strains 
MIC (μg/mL) 
kanamycin 10a 10b 10c 10d 10e 10f 10g 9cB 9cE 
1 E. coli 10 
100-
200 
100-
200 
400-
800 
400-
800 
400-
800 
400-
800 
400-
800 
- - 
2 
E. coli 
kanr 
400–800 
400-
800 
200-
400 
>800 - - - - >800 >800 
Experimental Section 
General 
TLC analyses are performed on silica gel-coated plates (Merck 60 F254) with the indicated solvent 
mixture. Compounds were detected with ammonium molybdate or potassium permanganate staining, 
or UV light. Flash column chromatography was carried out using ACROS silica gel (0.035–0.070 mm, 
ca 6 nm pore diameter). Solvents were distilled from appropriate drying agents prior to use. Unless 
stated otherwise, all chemicals were purchased and used as such. IR spectra were recorded on an ATI 
Mattson Genesis Series FTIR spectrometer; absorption reported in cm-1. NMR spectra were recorded 
on a Bruker DMX 300 (75 MHz), and a Varian 400 (400 MHz) spectrometer. 1H-NMR and 13C-NMR 
spectra are reported in ppm units on the δ scale. Coupling constants are reported as J-values in Hz. 
Semipreparative RP-HPLC was performed using a C18 column (10 × 250 mm, 5 µm) with HPLC grade 
MilliQ containing 0.1% TFA (eluant A) and acetonitrile containing 0.1% TFA (eluant B) with a 
gradient of 5 → 50% of B in 30 min. Compounds were detected by UV absorption at 215 and 254 nm. 
Hexa-N-(tert-butoxycarbonyl) neomycin B (1) [49]  
To a solution of neomycin B (2 g, 2.2 mmol) in a mixture of H2O/1,4-dioxane (30 mL, 1:1 v/v) was 
added Na2CO3 and di-tert-butyl dicarbonate. The reaction mixture was stirred at room temperature for 
6 h. Dioxane was removed by evaporation and the residue was partitioned between EtOAc (100 mL) 
and H2O (100 mL). The aqueous layer was extracted with EtOAc (2 ×50 mL) and the combined 
organic layers werewashed with brine (100 mL), dried (Na2SO4) and concentrated in vacuo. 
Purification by column chromatography (MeOH/CH2Cl2, 1/9) afforded 1 (2.2 g, 82%) as an 
amorphous white solid. RF 0.49 (MeOH/CH2Cl2, 1/9). HRMS (ESI) m/z calcd. for C53H94N6O25 
(M+Na)+: 1237.6166, found: 1237.6141. 
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5-O-(β-D-ribofuranosyl)-2-deoxystreptamine (2) 
 To a solution of 1 (1 g, 0.82 mmol) in 25 mL of MeOH, was added 25 mL of a H2O solution of 
NaIO4 (2.12 g, 9.8 mmol). The reaction mixture was stirred at room temperature for 16 h. Methanol 
was removed by evaporation and the residue was partitioned between EtOAc (100 mL) and H2O  
(50 mL). The aqueous layer was extracted with EtOAc (2 × 50 mL) and the combined organic layers 
werewashed with brine (100 mL), dried (Na2SO4) and concentrated in vacuo. The residue was 
dissolved in MeOH (30 mL), and Et3N (2 mL) was added. The reaction mixture was stirred at room 
temperature for 16 h and then concentrated in vacuo. Purification by crystallization from CH2Cl2  
(100 mL) afforded compound 2 (212 mg, 52%) as a white amorphous solid. RF 0.12 (MeOH/CH2Cl2, 
1/9); 1H-NMR (MeOD, 400 MHz) δ 5.21 (s, 1H), 4.32 (dd, J =4.5, 7.7 Hz, 1H), 3.99 (d, J =4.5 Hz, 
1H), 3.90 (dt, J =2.6, 7.7 Hz, 1H), 3.78 (dd, J =2.3, 12.1 Hz, 1H), 3.60 (dd, J =2.6, 12.1 Hz, 1H), 3.40–
3.15 (m, 10H), 2.02 (dt, J =4.2, 7.9 Hz, 1H), 1.41 (s, 18H), 1.21 (m, 1H); 13C-NMR (MeOD, 75 MHz): 
δ 156.3, 107.8, 83.8, 82.3, 78.2, 74.7, 72.7, 68.6, 59.7, 50.6, 33.8,26.8; HRMS (ESI) m/z calcd. for 
C21H38N2O11 (M+Na)+: 517.2373, found: 517.2375. 
5-O-(N-propyn-1-yl -morpholino)-2-deoxystreptamine (3) 
To a solution of 2 (830 mg, 1.68 mmol) in 20 mL of MeOH, was added 20 mL of a H2O solution of 
NaIO4 (431 mg, 2.016 mmol). The reaction mixture was stirred at room temperature for 2 h. The 
methanol was removed by evaporation and the residue was partitioned between EtOAc (100 mL) and 
H2O (50 mL). The aqueous layer was extracted with EtOAc (2 ×50 mL) and the combined organic 
layers werewashed with brine (100 mL), dried (Na2SO4) and concentrated in vacuo. The residue was 
dissolved in 15 mL of MeOH, and NaBH3CN (422 mg, 6.72 mmol) was added. To the resulting 
mixture was added drop-wise a solution of propargylamine (138 μL, 2.52 mmol) and AcOH (403 μL, 
6.72 mmol) in MeOH (1 mL). The reaction mixture was stirred at room temperature for 2 h. The 
reaction was then quenched with 0.5 mL of Et3N and concentrated in vacuo. The residue was taken up 
in EtOAc (100 mL), washed with saturated NaHCO3 (2 × 50 mL) and brine (50 mL). The organic layer 
was dried (Na2SO4), filtered and concentrated in vacuo.Purification by column chromatography 
(MeOH/CH2Cl2, 1/9) afforded 1 (358 mg, 41%) as an amorphous white solid. RF 0.34 (MeOH/CH2Cl2, 
1/9); 1H-NMR (MeOD, 400 MHz) δ 4.85 (dd, J = 2.3, 8.6 Hz, 1H), 3.70 (m, 1H), 3.57 (dd, J = 1.7, 
5.1Hz, 2H), 3.42–3.19 (m, 11H), 3.01 (d, J = 10.5 Hz, 1H), 2.70 (d, J = 11.1 Hz, 1H), 2.65 (t, J = 2.3 
Hz, 1H), 2.13 (m, 2H), 2.02 (dt, J = 3.9, 13.0 Hz, 1H), 1.41 (s, 18H), 1.21 (dd, J = 12.5 Hz, 1H). 13C-
NMR (MeOD, 75 MHz): δ 156.2, 99.7, 85.2, 78.1, 76.7, 74.1, 73.5, 72.5, 61.9, 54.1, 51.3, 50.6, 50.4, 
45.1, 33.6, 26.8; HRMS (ESI) m/z calcd. for C24H41N3O9 (M+H)+: 516.2921, found: 516.2925.  
2-(2-Aminoethylamino)-4-methylpyridine (5) 
A solution of 2-chloro-4-methylpyridine (0.876 mL, 10 mmol) in 1,2-diaminoethane (6 mL) was 
heated at 150°C for 18 h. The volatiles were removed in vacuo. Purification by column 
chromatography (10% MeOH/CH2Cl2 to 20% MeOH/CH2Cl2) afforded 5 (700 mg, 46%) as a yellow 
oil; 1H-NMR (MeOD, 300 MHz) δ 7.76 (d, J = 4.8 Hz, 1H), 6.36 (m, 2H), 3.31 (t, J = 6.2 Hz, 2H), 
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2.79 (t, J = 6.2 Hz, 2H), 2.17 (s, 3H); 13C-NMR (MeOD, 75 MHz): δ 156.5, 145.0, 136.2, 121.1, 
106.6, 40.1, 39.9, 15.5.HRMS (ESI) m/z calcd. for C8H13N3 (M+H)+: 152.1187, found: 152.1199. 
2-(2-Aminoethylamino)-5-methylpyridine (6) 
 A solution of 2-chloro-5-methylpyridine (0.434 mL, 5 mmol) in 1,2-diaminoethane (3 mL) was 
heated at 150°C for 18 h. The volatiles were removed in vacuo. Purification by column 
chromatography (10% MeOH/CH2Cl2 to 20% MeOH/CH2Cl2) afforded 6 (386 mg, 51%) as a yellow 
oil; 1H-NMR (MeOD, 300 MHz) δ 7.72 (m, 1H), 7.27 (dd, J = 2.5, 8.5 Hz, 1H), 6.46 (d, J = 8.5 Hz, 
1H), 3.30 (t, J = 6.2 Hz, 2H), 2.79 (t, J = 6.2 Hz, 2H), 2.13 (s, 3H). 13C-NMR (MeOD, 75 MHz): 
δ 156.6, 145.3, 138.0, 120.3, 107.7, 43.5, 40.1, 15.5; HRMS (ESI) m/z calcd. For C8H13N3 (M+H)+: 
152.1187, found: 152.1199. 
2-(2-Aminoethylamino)-4-methylquinoline (7) 
 A solution of 2-chloro-4-methylquinoline (1.7 g, 10 mmol) in 1,2-diaminoethane (6 mL) was 
heated at 150°C for 18 h. The volatiles were removed in vacuo. Purification by column 
chromatography (10% MeOH/CH2Cl2 to 20% MeOH/CH2Cl2) afforded 7 (963 mg, 48%) as a yellow 
oil; 1H-NMR (MeOD, 300 MHz) δ 7.72 (dd, J = 1.2, 8.1 Hz, 1H), 7.59 (dq, J = 0.5, 1.2, 8.4 Hz, 1H), 
7.45 (ddd, J = 1.4, 6.9, 8.4 Hz, 1H), 7.17 (ddd, J = 1.2, 6.9, 8.1 Hz, 1H), 6.59 (d, J = 1.0 Hz, 1H), 3.50 
(t, J = 6.2 Hz, 2H), 2.86 (t, J = 6.2 Hz, 2H), 2.48 (d, J = 1.0 Hz, 3H). 13C-NMR (MeOD, 75 MHz): 
δ 156.9, 147.0, 144.2, 128.4, 124.5, 123.0, 122.8, 120.9, 111.9, 42.6, 40.3, 16.9; HRMS (ESI) m/z 
calcd. for C12H15N3 (M+H)+: 202.1344, found: 202.1335. 
5-O-(N-propyn-1-yl-2-(methylamino-N-ethylamino-N -4-methylpyridin-2-yl)-morpholino)-2-
deoxystreptamine 8a 
To a solution of 3 (65 mg, 0.126 mmol) in DMF (1 mL), was added Dess-Martin periodinane  
(64 mg, 0.151mmol). The reaction mixture was stirred overnight at room temperature. The reaction 
was quenched with a saturated solution of NaHCO3 (20 mL) and extracted with EtOAc (3 ×25 mL). 
The combined organic layers were washed with H2O (2 × 25 mL) and brine (25 mL), dried (Na2SO4) 
and concentrated in vacuo. The residue was dissolved in 2 mL of MeOH, and NaBH3CN (12 mg, 0.189 
mmol) was added. To the reaction mixture was added a solution of 5 (57 mg, 0.378 mmol) and AcOH 
(11 μL, 0.189 mmol) in MeOH (0.5 mL). The reaction mixture was stirred at room temperature for 4 h. 
The reaction was quenched with 0.1 mL of Et3N and concentrated in vacuo. The residue was taken up 
in EtOAc (50 mL), washed with saturated NaHCO3 (2 × 25 mL) and brine (25 mL). The organic layer 
was dried (Na2SO4), filtered and concentrated in vacuo. Purification by column chromatography 
(MeOH/CH2Cl2, 1/9) afforded 8a (32 mg, 39%) as a white solid. RF 0.22 (MeOH/CH2Cl2, 1/9); 1H- 
NMR (MeOD, 400 MHz) δ 7.89 (d, J =  5.4 Hz, 1H), 6.52 (d, J = 5.4 Hz, 1H), 6.47 (s, 1H), 5.03 (d,  
J = 7.5 Hz, 1H), 3.96 (m, 1H), 3.57 (q, J = 5.6, 10.3 Hz, 2H), 3.41–3.15 (m, 12H), 2.94 (d, J = 10.3 
Hz, 1H), 2.70 (m, 2H), 2.29 (dd, J = 7.7, 11.0 Hz, 1H), 2.22 (s, 3H), 1.99 (m. 1H), 1.41 (d, J= 8.4 Hz, 
18H), 1.24 (m, 1H); 13C-NMR (MeOD, 75 MHz): δ 156.3, 156.2, 149.1, 144.9, 126.9, 114.3, 109.2, 
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99.5, 83.2, 78.2, 76.4, 74.8, 73.7, 72.8, 69.1, 54.0, 51.5, 48.7, 45.0, 38.2, 33.8, 26.8, 19.2; HRMS (ESI) 
m/z calcd. for C32H52N6O8 (M+H)+: 649.3924, found: 649.3923. 
5-O-(N-propyn-1-yl-2-(methylamino-N-ethylamino-N -5-methylpyridin-2-yl)-morpholino)-2-
deoxystreptamine 8b 
 To a solution of 3 (80 mg, 0.155 mmol) in DMF (1 mL), was added Dess-Martin periodinane  
(79 mg, 0.186 mmol). The reaction mixture was stirred overnight at room temperature. The reaction 
was quenched with a saturated solution of NaHCO3 (20 mL) and extracted with EtOAc (3 × 25 mL). 
The combined organic layers were washed with H2O (2 × 25 mL) and brine (25 mL), dried (Na2SO4) 
and concentrated in vacuo. The residue was dissolved in 3 mL of MeOH, and NaBH3CN (14 mg, 0.232 
mmol) was added. To the resulting mixture was added a solution of 6 (70 mg, 0.465 mmol) and AcOH 
(14 μL, 0.232 mmol) in MeOH (0.5 mL). The reaction mixture was stirred at room temperature for 4 h. 
The reaction was quenched with 0.1 mL of Et3N and concentrated in vacuo. The residue was taken up 
in EtOAc (50 mL), washed with saturated NaHCO3 (2 × 25 mL) and brine (25 mL). The organic layer 
was dried (Na2SO4), filtered and concentrated in vacuo. Purification by column chromatography 
(MeOH/CH2Cl2, 1/9) afforded 8b (41 mg, 41%) as a white solid. RF 0.22 (MeOH/CH2Cl2, 1/9); 1H- 
NMR (MeOD, 400 MHz) δ 7.74 (s, 1Η),7.28 (dd, J = 2.3, 8.5 Hz, 1H), 6.5 (d, J = 8.5 Hz, 1H), 4.85 
(dd, J = 2.3, 8.6 Hz, 1H), 3.80 (m, 1H), 3.42–3.19 (m, 11H), 2.99 (d, J = 10.3 Hz, 1H), 2.18–2.00 (m, 
5H), 1.40 (d, J = 7.2 Hz, 18H), 1.26 (m, 1H); 13C-NMR (MeOD, 75 MHz): δ 156.6, 156.3, 156.1, 
145.1, 138.2, 120.5, 108.1, 99.8, 85.2, 78.2, 76.6, 76.2, 74.2, 73.5, 72.6, 71.7, 54.1, 52.5, 50.5, 50.0, 
45.0, 39.9, 33.8, 26.8, 15.4; HRMS (ESI) m/z calcd. for C32H52N6O8 (M+H)+: 649.3924, found: 
649.3923. 
5-O-(N-propyn-1-yl-2-(methylamino-N-ethylamino-N-4-methylquinolin-2-yl)-morpholino)-2-
deoxystreptamine 8c 
 To a solution of 3 (100 mg, 0.194 mmol) in DMF (1 mL), was added Dess-Martin periodinane  
(99 mg, 0.232 mmol). The reaction mixture was stirred overnight at room temperature. The reaction 
was quenched with saturated solution of NaHCO3 (20 mL) and extracted with EtOAc (3 × 25 mL). The 
combined organic layers were washed with H2O (2 × 25 mL) and brine (25 mL), dried (Na2SO4) and 
concentrated in vacuo. The residue was dissolved in 4 mL of MeOH, and NaBH3CN (18 mg, 0.291 
mmol) was added. To the resulting mixture was added a solution of 7 (116 mg, 0.582 mmol) and 
AcOH (17.5 μL, 0.291 mmol) in MeOH (0.5 mL). The reaction mixture was stirred at room 
temperature for 4 h. The reaction was quenched with 0.1 mL of Et3N and concentrated in vacuo. The 
residue was taken up in EtOAc (50 mL), washed with saturated NaHCO3 (2 × 25 mL) and brine  
(25 mL). The organic layer was dried (Na2SO4), filtered and concentrated in vacuo. Purification by 
column chromatography (MeOH/CH2Cl2, 1/9) afforded 8c (52 mg, 38%) as a white solid. RF 0.21 
(MeOH/CH2Cl2, 1/9); 1H-NMR (MeOD, 400 MHz) δ 7.84 (d, J = 8.1 Hz, 1H), 7.62 (d, J = 3.4 Hz, 
1H), 7.30 (q, J = 4.1, 8.1 Hz, 1H), 6.72 (d, J = 1.0 Hz, 1H), 5.06 (d, J = 6.3 Hz, 1H), 3.97 (m, 1H), 
3.75 (t, J = 5.0 Hz, 2H), 3.44–3.18 (m, 13H), 2.95 (d, J = 11.0 Hz, 1H), 2.72–2.65 (m, 2H), 2.57 (d,  
J = 1.0 Hz, 3H), 2.30 (dd, J = 7.7, 11.0 Hz, 1H), 2.17 (dd, J = 9.3, 11.1 Hz, 1H), 2.03 (dt, J = 3.8, 12.5 
Hz, 1H), 1.42 (d, J = 9.1 Hz, 18H), 1.32 (m, 1H); 13C-NMR (MeOD, 75 MHz): δ 156.7, 145.9, 145.2, 
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129.4, 123.7, 123.3, 123.1, 122.0, 112.0, 99.6, 83.5, 78.2, 76.4, 74.7, 73.7, 72.8, 69.2, 54.0, 51.6, 49.1, 
48.5, 45.0, 38.4, 26.9, 17.0; HRMS (ESI) m/z calcd. for C36H54N6O8 (M+H)+: 699.4081, found: 
699.4062. 
General procedure for Boc-protection of 9a-c 
To a solution of 8a-c (0.15 mmol) in CH2Cl2 (2 mL) was added di-tert-butyl dicarbonate  
(0.18 mmol, 1.2 equiv.) and DMAP (5 mg). The reaction mixture was stirred at room temperature for 5 
h. The volatiles were removed in vacuo. Purification by column chromatography (MeOH/CH2Cl2, 1/9) 
gave the desired product. 
5-O-(N-propyn-1-yl-2-(methylamino-N-(Tert-Butoxycarbonyl)ethylamino-N -4-methylpyridin-2-yl)- 
morpholino)-2-deoxystreptamine 9a: Yield 87%, white solid. RF 0.43 (MeOH/CH2Cl2, 1/9); HRMS 
(ESI) m/z calcd. for C37H60N6O10 (M+H)+: 749.4449, found: 749.4434. 
5-O-(N-propyn-1-yl-2-(methylamino-N-(Tert-Butoxycarbonyl)ethylamino-N -5-methylpyridin-2-yl)-
orpholino)-2-deoxystreptamine 9b: Yield 90%, white solid. RF 0.43 (MeOH/CH2Cl2, 1/9); HRMS 
(ESI) m/z calcd. for C37H60N6O10 (M+H)+: 749.4449, found: 749.4434. 
5-O-(N-propyn-1-yl-2-(methylamino-N-(Tert-Butoxycarbonyl)ethylamino-N -4-methylquinolin-2-yl)-
morpholino)-2-deoxystreptamine 9c: Yield 84%, white solid. RF 0.46 (MeOH/CH2Cl2, 1/9); HRMS 
(ESI) m/z calcd. for C41H62N6O10 (M+H)+: 799.4605, found: 799.4587. 
3.3. General procedure for the synthesis of bis-azides A-D 
To a solution of a commercially obtained dibromide (2.5 mmol) in 10 mL of DMF was added NaN3 
(6.0 mmol). The reaction mixture was stirred at 60 °C for 5 h. The reaction was then quenched with 
H2O and extracted with Et2O. The organic layers were washed with H2O and brine, dried (Na2SO4) and 
concentrated in vacuo. Purification by column chromatography (EtOAc/heptane, 1/20) gave the pure 
product. 
1,4-bis(Azidomethyl)benzene (A): Yield 86%, oil. RF 0.34 (EtOAc/heptane, 1/8); 1H-NMR (CDCl3, 300 
MHz) δ 7.34 (s, 4H), 4.35 (s, 4H); 13C-NMR (CDCl3, 75 MHz): δ 135.0, 128.1, 53.9. 
1,2-bis(Azidomethyl)benzene (B): Yield 82%, oil. RF 0.36 (EtOAc/heptane, 1/8); 1H-NMR (CDCl3, 300 
MHz) δ 7.38 (s, 4H), 4.43 (s, 4H); 13C-NMR (CDCl3, 75 MHz): δ 133.4, 129.6, 128.5, 51.7. 
1,5-Diazidopentane (C): Yield 91%, liquid. RF 0.49 (EtOAc/heptane, 1/8); 1H-NMR (CDCl3, 300 
MHz) δ3.25 (t, J = 6.7 Hz, 4H), 1.60 (m, 4H), 1.42 (m, 2H); 13C-NMR (CDCl3, 75 MHz) δ 50.7, 27.9, 
23.4. 
1,4-Diazidobutane (D): Yield 86%, liquid. RF 0.51 (EtOAc/heptane, 1/8); 1H-NMR (CDCl3, 300 MHz) 
δ 3.27(t, J = 5.7 Hz, 4H), 1.61 (m, 4H); 13C-NMR (CDCl3, 75 MHz) δ 50.4, 25.6. 
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1-Bromo-4-(azidomethyl)bromobenzene 
To a solution of 1-bromo-4-(bromomethyl)benzene (200 mg, 0.80 mmol) in 1 mL of DMF was 
added NaN3 (52 mg, 0.80 mmol). The reaction mixture was stirred at 60 °Cfor 5 h. The reaction was 
then quenched with H2O and extracted with Et2O. The organic layers were washed with H2O and 
brine, dried (Na2SO4)and concentrated in vacuo. Purification by column chromatography 
(EtOAc/heptane, 1/20) gave 1-bromo-4-(azidomethyl)benzene (156 mg, 92%) as a colorless liquid. RF 
0.51 (EtOAc/heptane, 1/8); 1H-NMR (CDCl3, 400 MHz) δ 7.47 (d, J = 8.4 Hz, 2H), 7.15 (d, J = 8.4 
Hz, 2H), 4.24 (s, 2H); 13C-NMR (CDCl3, 75 MHz) δ 133.9, 131.5, 129.3, 121.8, 53.6. 
1-Azido-4-bromobenzene 
To a solution of NaN3 (1.5 g, 24.3mmol) in a mixture of H2O/CH2Cl2 (7.5 mL, 1:1 v/v) at 0 °C, was 
added Tf2O (2.01 mL, 12.15mmol). The reaction mixture was stirred at room temperature for 2 h. 
After quenching with aqueous NaHCO3, the layers were separated and the aqueous layer was extracted 
with CH2Cl2 (5.75 mL). The organic layers were combined to afford 9.5 mL of TfN3 solution. Then, to 
a solution of para-bromoaniline (700mg, 4.06mmol) and CuSO4 (5 mg) in H2O (9.5 mL) was added 
the TfN3 solution, MeOH (31 mL) and Et3N (1.6 mL). The reaction mixture was stirred overnight at 
room temperature. Then solid NaHCO3 (1.0 g) was added carefully and the organic solvents were 
evaporated. The aqueous residue was extracted with EtOAc (3 × 100 mL), and the organic layers were 
combined, dried (Na2SO4), and concentrated in vacuo to give a yellow liquid. Purification by column 
chromatography (EtOAc/heptane, 1/20) afforded 1-azido-4-bromobenzene (630mg, 78%) as a 
colorless liquid. RF 0.61 (EtOAc/heptane, 1/8); 1H-NMR (CDCl3, 400 MHz) δ 7.44 (d, J = 8.9 Hz, 2H), 
6.89 (d, J = 8.9 Hz, 2H); 13C-NMR (CDCl3, 75 MHz) δ 138.7, 132.3, 120.1, 117.2. 
1-(Azidomethyl)-4-methoxybenzene 
To a solution of 1-(chloromethyl)-4-methoxybenzene (400 μL, 2.9 mmol) in 2 mL of DMF was 
added NaN3 (188 mg, 2.9 mmol). The reaction mixture was stirred at 60 °C for 5 h. The reaction was 
then quenched with H2O and extracted with Et2O. The organic layers were washed with H2O and 
brine, dried (Na2SO4) and concentrated in vacuo. Purification by column chromatography 
(EtOAc/heptane, 1/20) gave 1-(azidomethyl)-4-methoxybenzene (410 mg, 87%) as a colorless liquid. 
RF 0.36 (EtOAc/heptane, 1/8); 1H-NMR (CDCl3, 400 MHz) δ 7.23(d, J = 8.8 Hz, 2H), 6.90 (d, J = 8.8 
Hz, 2H), 4.24 (s, 2H), 3.78 (s, 3H); 13C-NMR (CDCl3, 75 MHz) δ 159.2, 129.2, 126.9, 113.7, 54.7, 
53.9. 
1-Azido-4-methoxybenzene 
To a solution of NaN3 (1.5 g, 24.3mmol) in a mixture of H2O/CH2Cl2 (7.5 mL, 1:1 v/v) at 0 °C, was 
added Tf2O (2.01 mL, 12.15mmol). The reaction mixture was stirred at room temperature for 2 h. 
After quenching with aqueous NaHCO3, the layers were separated and the aqueous layer was extracted 
with CH2Cl2 (5.75 mL). The organic layers were combined to afford 9.5 mL of TfN3 solution. Then, to 
a solution of para-methoxyaniline (500mg, 4.06mmol) and CuSO4 (5 mg) in H2O (9.5 mL) was added 
the TfN3 solution, MeOH (31 mL) and Et3N (1.6 mL). The reaction mixture was stirred overnight at 
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room temperature. Then solid NaHCO3 (1.0 g) was added carefully and the organic solvents were 
evaporated. The aqueous residue was extracted with EtOAc (3 × 100 mL), and the organic layers were 
combined, dried (Na2SO4), and concentrated in vacuo to give yellow liqued. Purification by column 
chromatography (EtOAc/heptane, 1/20) afforded 1-azido-4-methoxybenzene (490mg, 81%) as a 
colorless liquid. RF 0.42 (EtOAc/heptane, 1/8); 1H-NMR (CDCl3, 400 MHz) δ 6.94 (m, 2H), 6.87 (m, 
2H), 3.78 (s, 3H); 13C-NMR (CDCl3, 75 MHz) δ156.5, 131.8, 119.5, 114.6, 55.0. 
1-(Azidomethyl)-2-methoxybenzene 
To a solution of 1-(chloromethyl)-2-methoxybenzene (400 μL, 2.9 mmol) in 2 mL of DMF was 
added NaN3 (188 mg, 2.9 mmol). The reaction mixture was stirred at 60 °C for 5 h. The reaction was 
then quenched with H2O and extracted with Et2O. The organic layers were washed with H2O and 
brine, dried (Na2SO4) and concentrated in vacuo. Purification by column chromatography 
(EtOAc/heptane, 1/20) gave 1-(azidomethyl)-2-methoxybenzene (406 mg, 86%) as a colorless liquid. 
RF 0.44 (EtOAc/heptane, 1/8). 1H-NMR (CDCl3, 400 MHz) δ 7.29(m, 2H), 6.94 (m, 2H), 4.35 (s, 2H), 
3.84 (s, 3H).13C-NMR (CDCl3, 75 MHz) δ 157.2, 129.6, 129.3, 123.4, 120.1, 110.1, 54.8, 49.7. 
General Procedure for Copper (I)-Catalyzed Azido-Alkyne Cycloaddition (CuAAC) (Compounds 9aA-
10g), exemplified for compound 9aA 
To a solution of 9a (15 mg, 0.020 mmol) in a mixture of MeCN/H2O (2 mL, 20:1 v/v), was added 
linker A (1.8 mg, .010 mmol). The reactionmixture was stirred at room temperature in the presence of 
a Cu-wired stirringbar. After 3 h, the Cu-wire was removed and stirring wasprolonged until all starting 
material was consumed. The volatiles were removed in vacuo. Purification by column chromatography 
(MeOH/CH2Cl2, 1/9) afforded 9aA (11 mg, 63%) as a white solid. HRMS (ESI) m/z calcd. for 
C52H80N18O8 (M+H)+: 1085.6484, found: 1085.6464; RP-HPLC: tR  = 15.42 min. 
Dimer 9aB: Yield 57%, white solid. HRMS (ESI) m/z calcd. for C52H80N18O8 (M+H)+: 1085.6484, 
found: 1085.6482; RP-HPLC: tR = 17.23 min. 
Dimer 9aC: Yield 61%, white solid. 1H-NMR (MeOD, 400 MHz): δ 7.95 (s, 2H), 7.78 (d, J = 6.4 Hz, 
2H), 6.91 (s, 2H), 6.81 (dd, J = 6.6, 1.4 Hz, 2H), 5.09 (d, J = 7.7 Hz, 2H), 4.36 (t, J = 7.0 Hz, 4H), 4.10 
(m, 2H), 3.89 (s, 2H), 3.77 (t, J = 6.0 Hz, 4H), 3.65 (t, J = 9.2 Hz, 2H), 3.48 (m, 6H), 3.35 (m, 4H), 
3.21 (m, 6H), 2.39 (s, 6H), 2.36 (dt, J = 8.2, 3.8 Hz, 2H), 1.91 (m, 4H), 1.72 (q, J = 12.4 Hz, 2H), 1.27 
(m, 2H). HRMS (ESI) m/zcalcd for C49H82N18O8 (M+H)+: 1051.6641, found: 1051.6577; RP-HPLC: tR 
= 16.33 min. 
Dimer 9aD: Yield 60%, white solid. HRMS (ESI) m/z calcd. for C48H80N18O8 (M+H)+: 1037.6484, 
found: 1037.6448; RP-HPLC: tR = 16.28 min. 
Dimer 9aE: Yield 87%, white solid. HRMS (ESI) m/z calcd. for C29H43N9O4 (M+H)+: 582.3516, 
found: 582.3516; RP-HPLC: tR = 15.12 min. 
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Dimer 9bA: Yield 73%, white solid. HRMS (ESI) m/z calcd. for C52H80N18O8 (M+H)+: 1085.6412, 
found: 1085.6419; RP-HPLC: tR = 16.72 min. 
Dimer 9bB: Yield 65%, white solid. HRMS (ESI) m/z calcd. for C52H80N18O8 (M+H)+: 1085.6484, 
found: 1085.6442; RP-HPLC: tR = 16.44 min. 
Dimer 9bC: Yield 66%, white solid. HRMS (ESI) m/z calcd. for C49H82N18O8 (M+H)+: 1051.6641, 
found: 1051.6641; RP-HPLC: tR = 17.11 min. 
Dimer 9bD: Yield 65%, white solid. HRMS (ESI) m/z calcd. for C48H80N18O8 (M+H)+: 1037.6484, 
found: 1037.6460; RP-HPLC: tR = 16.81 min. 
Dimer 9bE: Yield 92%, white solid. HRMS (ESI) m/z calcd. for C29H43N9O4 (M+H)+: 582.3516, 
found: 582.3516; RP-HPLC: tR = 16.19 min. 
Dimer 9cA: Yield 60%, white solid. HRMS (ESI) m/z calcd. for C60H84N18O8 (M+H)+: 1185.6797, 
found: 1185.6878; RP-HPLC: tR = 22.72 min. 
Dimer 9cB: Yield 58%, white solid; HRMS (ESI) m/z calcd. for C60H84N18O8 (M+H)+: 1185.6797, 
found: 1185.6781; RP-HPLC: tR = 24.13 min. 
Dimer 9cC: Yield 69%, white solid. 1H-NMR (MeOD, 400 MHz): δ 8.09 (s, 2H), 7.96 (d, J = 8.1 Hz, 
2H), 7.82 (s, 2H), 7.71 (t, J = 7.2 Hz, 2H), 7.49 (t, J = 8.1 Hz, 2H), 6.99 (s, 2H), 5.24 (d, J = 7.4 Hz, 
2H), 4.44 (s, 2H), 4.34 (t, J = 7.0 Hz, 4H), 3.95 (s, 4H), 3.65 (t, J = 9.1 Hz, 4H), 3.38–3.60 (m, 8H), 
3.27 (t, J = 6.6 Hz, 4H), 3.16 (m, 4H), 2.95 (s, 2H), 2.63 (s, 4H), 2.32 (dt, J = 12.2, 4.1 Hz, 2H), 1.87 
(m, 4H), 1.69 (q, J = 12.2 Hz, 2H), 1.26 (m, 2H); HRMS (ESI) m/z calcd. for C57H86N18O8 (M+H)+: 
1151.6954, found: 1151.6945; RP-HPLC: tR = 21.61 min. 
Dimer 9cD: Yield 66%, white solid; HRMS (ESI) m/z calcd. for C56H84N18O8 (M+H)+: 1137.6797, 
found: 1137.6793; RP-HPLC: tR = 23.12 min. 
Dimer 9cE: Yield 90%, white solid; HRMS (ESI) m/z calcd. for C33H45N9O4 (M+H)+: 632.3672, 
found: 632.3669; RP-HPLC: tR = 19.87 min. 
Compound 10a:Yield 79%, white solid; 1H-NMR (MeOD, 400 MHz): δ 8.04 (s, 1H), 8.02 (d, J = 8.4 
Hz, 1H), 7.77 (t, J = 7.7 Hz, 1H), 7.55 (t, J = 7.7 Hz, 1H), 7.50 (d, J = 8.2 Hz, 2H), 7.24 (d, J = 8.2 Hz, 
2H), 5.55 (s, 2H), 5.16 (d, J = 7.2 Hz, 1H), 4.17 (s, 3H), 3.98 (t, J = 6.0 Hz, 2H), 3.65 (t, J = 9.0 Hz, 
1H), 3.56 (m, 1H), 3.48 (t, J = 9.7 Hz, 4H), 3.37 (dd, J = 12.8, 2.3 Hz, 1H), 3.20 (m, 4H), 2.69 (s, 3H), 
2.60 (m, 2H), 2.36 (dt, J = 8.1, 3.7 Hz, 1H), 1.71 (q, J = 12.4 Hz, 1H); HRMS (ESI) m/z calcd. for 
C33H44N9O4Br (M+H)+: 710.2777, found: 710.2761; RP-HPLC: tR = 20.43 min. 
Compound 10b: Yield 71%, white solid; HRMS (ESI) m/z calcd. for C32H42N9O4Br (M+H)+: 
696.2621, found: 696.2664; RP-HPLC: tR = 21.18 min. 
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Compound 10c: Yield 77%, white solid; 1H-NMR (MeOD, 400 MHz): δ 8.03 (s, 1H), 8.01 (d, J = 8.1 
Hz, 1H), 7.76 (t, J = 7.7 Hz, 1H), 7.54 (t, J = 7.7 Hz, 1H), 7.28 (d, J = 8.7 Hz, 2H), 6.88 (d, J = 8.7 Hz, 
2H), 5.49 (s, 2H), 5.23 (d, J = 7.0 Hz, 1H), 4.36 (s, 2H), 4.28 (t, J = 9.5 Hz, 1H), 3.99 (t, J = 5.5 Hz, 
2H), 3.74 (s, 3H), 3.66 (t, J = 9.1 Hz, 1H), 3.63 (d, J = 11.5 Hz, 1H), 3.57 (dd, J = 12.8, 6.4 Hz, 1H), 
3.36–3.55 (m, 4H), 3.31 (s, 3H), 2.84 (m, 2H), 2.68 (s, 2H), 2.37 (dt, J = 12.0, 4.0 Hz, 1H), 1.73 (q, J = 
12.5 Hz, 1H); HRMS (ESI) m/z calcd. for C34H47N9O5 (M+H)+: 662.3778, found: 662.3758; RP-
HPLC: tR = 21.34 min. 
Compound 10d: Yield 72%, white solid; HRMS (ESI) m/z calcd. for C33H45N9O5 (M+H)+: 648.3621, 
found: 648.3600; RP-HPLC: tR = 20.63 min. 
Compound 10e: Yield 81%, white solid; 1H-NMR (MeOD, 400 MHz): δ 8.02 (d, J = 8.2 Hz, 1H), 7.97 
(s, 1H), 7.77 (dd, J = 8.2, 7.2 Hz, 1H), 7.55 (dd, J = 8.2, 7.2 Hz, 1H), 7.33 (m, 1H), 7.23 (dd, J = 7.4, 
1.6 Hz, 1H), 7.00 (d, J = 8.3 Hz, 1H), 6.92 (dt, J = 7.5, 1.0 Hz, 1H), 5.55 (s, 2H), 5.19 (d, J = 8.3 Hz, 
1H), 4.24 (s, 3H), 3.99 (t, J = 5.9 Hz, 2H), 3.83 (s, 3H), 3.68 (t, J = 9.2 Hz, 1H), 3.35–3.60 (m, 5H), 
2.84 (m, 3H), 2.69 (s, 4H), 2.36 (dt, J = 12.1, 4.0 Hz, 1H), 1.71 (q, J =12.6 Hz, 1H); HRMS (ESI) 
m/zcalcd for C34H47N9O5 (M+H)+: 662.3778, found: 662.3769; RP-HPLC: tR = 21.15 min. 
Compound 10f: Yield 70%, white solid; HRMS (ESI) m/z calcd. for C34H48N10O4 (M+H)+: 661.3938, 
found: 661.3914; RP-HPLC: tR = 21.32 min. 
Compound 10g: Yield 68%, white solid; HRMS (ESI) m/z calcd. for C31H50N10O4 (M+H)+: 627.4094, 
found: 627.4084; RP-HPLC: tR = 21.12 min. 
FRET-based oxygen-sensitive assay [71] 
A typical experiment using a 96-well U-bottom plate was performed as follows. Serial dilutions of a 
freshly grown cell culture were made in LB to achieve 109 to 102 colony-forming units (cfu, confirmed 
by colony plate counting). Wells were prepared in triplicate by filling each well with 180 μl of the cell 
dilution plus 20 μL of Cy3-labeled hemocyanin solution (0.5–1 μM end-concentration). To avoid 
evaporation and rapid oxygen diffusion, 50 μL of mineral oil was added on top of each well. For 
antibiotic resistance tests, the initial number of cells was 107 cfu/well. Kanamycin was added to a final 
concentration of 0.05 to 5000 μg/mL. Controls were performed by adding Cy3 or Cy3-labeled BSA 
instead of Cy3-labeled hemocyanin to the cell culture as well as by using unlabeled hemocyanin. The 
fluorescence of Cy3-labeled hemocyanin in LB without cells was also monitored as a control in the 
absence of oxygen consumption. 
Conclusions 
A set of dimers of aminoglycoside analogues has been synthesized from natural neomycin via a 
straightforward route. Cleavage of both diaminoglucose pyranoses was followed by installation of an 
N-propargylated morpholine. Subsequent selective oxidation of the primary alcohol and immediate 
conjugation to arylamine by reductive amination led to three different 2-deoxystreptamine conjugates. 
Dimerization of the resulting conjugates with a range of bisazides afforded a small library of potential 
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RNA-binding ligands in a straightforward synthetic route involving minimal protecting group 
transformations. All compounds were evaluated for antibacterial activity employing a novel 
fluorescence-based cell viability essay and compared to kanamycin. Several of the compounds, dimers 
and monomers, showed antibacterial activity, with values lying in the high micromolar range. Further 
optimization of the conjugates is therefore required, e.g., by introduction of longer spacers between the 
arylamines and the morpholine to allow cooperative binding. Similar reasoning may be applied to the 
dimers, as well as to the monofunctionalized morpholines. 
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